


VAS (mm)	All patients	> 5	> 10	> 15	> 20	> 25	> 30	> 35	> 40	> 45	> 50	> 55
Number (%) of patients	348 (100%)	211 (61%)	184 (53%)	162 (47%)	137 (39%)	122 (35%)	104 (30%)	86 (25%)	68 (20%)	61 (18%)	50 (14%)	39 (11%)

FIG.1



"How severe is your pain today? Please place a vertical mark on the line below to indicate how bad you feel your pain is today."
No pain
Very severe pain

FIG.2



Genetic fingerprint ?
yes
no
Masitinib plus gemcitabine treatment
Pain ?
yes
no
VAS > 20 ?
yes
no
Erlotinib plus gemcitabine or Folfirinox (ECOG ≤ 1)
Gemcitabine treatment

FIG.3



1.0
0.8
0.6
0.4
0.2
0.0
Survival Probability
Masitinib + Gemcitabine
Placebo + Gemcitabine
0
6
12
18
24
30
36
OS (months)

FIG.4



1.0
0.8
0.6
0.4
0.2
0.0
Survival Probability
Masitinib + Gemcitabine
Placebo + Gemcitabine
0
6
12
18
24
30
36
OS (months)

FIG.5



Masitinib + Gemcitabine
Placebo + Gemcitabine
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
6
12
18
24
30
36
OS (months)

FIG.6



Masitinib + Gemcitabine
Placebo + Gemcitabine
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
6
12
18
24
30
36
OS (months)

FIG.7



Masitinib + Gemcitabine
Placebo + Gemcitabine
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
6
12
18
24
30
36
OS (months)

FIG.8